液相色谱-串联质谱法测定毛发中的司坦唑醇

采用液相色谱-串联质谱(LC-MS/MS)建立了毛发中司坦唑醇的分析方法,并将其应用于单次给药动物实验中的动物毛样品分析。将10 mg样品碱水解后加入戊烷提取,然后进行LC-MS/MS分析,采用正离子电喷雾电离、多反应监测模式测定,方法的最低定量限为25 pg/mg。剃去豚鼠背部中央的毛,以60 mg/kg的剂量于豚鼠腹腔注射司坦唑醇,然后隔天在同一部位剃取其毛,两周内该豚鼠毛中均能检出司坦唑醇;给药后豚鼠毛中司坦唑醇的含量在第1周内保持稳定,在给药后第10天达到峰值。所建立的方法毛发取样量少,特异性强,灵敏度高,适用于毛发中司坦唑醇的分析。     

Quantification of micafungin in human plasma by liquid chromatography-tandem mass spectrometry

Micafungin (MCF) is an antifungal agent of the echinocandin class approved in Europe both in adults and in children for the treatment of invasive candidiasis. Few analytical methods for therapeutic drug monitoring (TDM) of this drug have been described so far. In this paper, we describe a rapid and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for the measurement of MCF in plasma. MCF was analyzed in 100-μL plasma samples over a wide range of concentrations (0.1–20 μg/mL) by LC-MS/MS after protein precipitation. The suitability of the assay for TDM was evaluated by using plasma samples from pediatric patients who received MCF for the treatment of invasive candidiasis. The overall turnaround time for the assay was 20 min. The lower limit of quantification of the method was 0.1 ng/mL. No ion suppression due to matrix effects was found with different pre-analytical conditions, such as hemolysis, lipemia, and hyperuricemia. A simple and rapid LC-MS/MS method which provides high specificity, precision, and accuracy for quantification of MCF in plasma has been developed and validated.     

超高效液相色谱-串联质谱法同时测定染发剂中6种染料

建立了同时测定染发剂中4,4'-二氨基二苯胺硫酸盐和2,4-二氨基苯酚硫酸盐等6种染料的超高效液相色谱-串联质谱(UPLC-MS/MS)分析方法.以水为提取剂进行超声提取,用Waters BEH-C₁₈柱(100 mm×2.1 mm, 1.7 μm)分离,以10 mmol/L的乙酸铵和乙腈为流动相进行梯度洗脱.在电喷雾正离子模式下,采用多反应监测(MRM)模式进行定性和定量分析.6种染料在相应的质量浓度范围内线性关系良好,线性相关系数(R²)均大于0.99,检出限为0.26~4.6 mg/kg,回收率为83.0%~92.2%,相对标准偏差为5.4%~11.2%.方法精密度、准确度、回收率和基质效应均符合染发剂样品测定的要求,用于实际样品测定,结果满意.本方法准确、简便、快速,适用于染发剂中6种染料的分析测定.     

Sensitive determination of phloroglucinol in human plasma by liquid chromatography-tandem mass spectrometry

Summary A sensitive and selective liquid chromatographic method coupled with tandem mass spectrometry (LC-MS-MS) was developed for the quantification of phloroglucinol in human plasma. Resorcinol was used as internal standard, with plasma samples extracted using ethyl acetate. A centrifuged upper layer was then evaporated and reconstituted with mobile phase. The reconsituted samples were injected into a C₁₈ XTerra MS column (2.1×100 mm) with 3.5 μm particle size. The analytical column lasted for at least 500 injections. The mobile phase was 15% acetonitrile (pH 3.0), with a flow rate at 100 μL min¹. The mass spectrometer was operated in positive ion mode using electrospray ionization. Using MS-MS in multiple reaction monitoring (MRM) mode, phloroglucinol was detected without severe interferences from the plasma matrix. Phloroglucinol produced a parent molecule ([M+H]⁺) atm/z 127 and a corresponding product ion atm/z 8l. Detection of phloroglucinol in human plasma was accurate and precise, with quantification on limit at 0.5 ng mL¹. The method has been successfully applied to a study of phloroglucinol in human specimens.     

液相色谱-串联质谱法检测人血浆及脂蛋白唾液酸的含量

建立了液相色谱-串联质谱(LC-MS/MS)检测人血浆脂蛋白唾液酸的方法,并比较了糖尿病患者与健康人血浆脂蛋白唾液酸的差异。采用pH=2的醋酸水解唾液酸,高速离心后采用优化的条件进行LC-MS/MS分析。结果表明:在负离子模式下,唾液酸的检出限和定量限分别为7.4和24.5 pg。唾液酸在2.5~80 ng/mL范围内呈良好的线性关系,相关系数R²大于0.998。糖尿病患者(平均年龄51.6岁)和健康人(平均年龄50.7岁)血浆中唾液酸的含量分别为(548.3±88.9)和(415.3±55.5)mg/L;两组实验人群中极低密度脂蛋白、低密度脂蛋白和高密度脂蛋白唾液酸的含量分别为(4.91±0.19)、(6.95±0.28)、(3.61±0.22)μg/mg和(2.90±0.27)、(7.03±0.04)、(2.40±0.09)μg/mg。糖尿病患者极低密度脂蛋白和高密度脂蛋白唾液酸含量显著高于同龄健康人水平(P<0.01)。该法可快速检测血浆中脂蛋白唾液酸含量,省时省力。     

高效液相色谱-串联质谱法分析毛发中甲基苯丙胺和苯丙胺手性对映异构体

建立了高效液相色谱-串联质谱（HPLC-MS/MS）分析毛发中甲基苯丙胺与苯丙胺对映异构体的手性分离方法。采用SUPELCO Astec CHIROBIOTIC^® V2手性液相色谱柱,以甲醇-含0.1%（v/v）甲酸的20 mmol/L乙酸铵水溶液（99：1,v/v）为流动相进行手性分离。结果表明,甲醇高温水浴超声法能较好地提取苯丙胺类化合物,且峰形较好（拖尾因子>0.95）。S-（+）-甲基苯丙胺、R-（-）-甲基苯丙胺、S-（+）-苯丙胺和R-（-）-苯丙胺在15~300 ng/mg范围内线性关系良好,相关系数均大于0.99;甲基苯丙胺和苯丙胺的检出限分别为0.1 ng/mg和0.15 ng/mg,定量限分别为0.4 ng/mg和0.5 ng/mg;日内精密度均≤6.8%,日间精密度均≤11.4%。采用所建方法对50余嫌疑人毛发进行手性分析,检出单一S-（+）-甲基苯丙胺和S-（+）-苯丙胺的占70%,同时检出S-（+）-甲基苯丙胺、R-（-）-甲基苯丙胺、S-（+）-苯丙胺和R-（-）-苯丙胺的占18%。该法简单快速,精密度好,可为实际法医毒物鉴定案例中的毛发手性分析提供技术支持与科学依据。     

Determination of benzophenones in human placental tissue samples by liquid chromatography-tandem mass spectrometry

Benzophenones (BPs) are a family of compounds widely used to protect the skin and hair from UV irradiation. Despite human exposure to BPs through dermal application of products containing sunscreen agents and the increasing evidence that BPs are able to interfere with endocrine systems, few studies have examined the occurrence of BPs in humans. In this work, we propose a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine six BPs, namely, benzophenone-1 (BP-1), benzophenone-2 (BP-2), benzophenone-3 (BP-3), benzophenone-6 (BP-6), benzophenone-8 (BP-8) and 4-hydroxybenzophenone (4-OH-BP) in human placental tissue samples. The method involves an extraction step of the analytes from the samples using ethyl acetate, followed by a clean-up step using centrifugation prior to their quantification by LC-MS/MS using an atmospheric pressure chemical ionization (APCI) interface in the positive mode. Benzophenone-d₁₀ (BP-d₁₀) was used as surrogate. Found detection limits (LOD) ranged from 0.07 to 0.3 ng g⁻¹ and quantification limits (LOQ) from 0.3 to 1.0 ng g⁻¹, while inter- and intra-day variability was under 5%. The method was validated using standard addition calibration and a recovery assay. Recovery rates for spiked samples ranged from 98 to 104%. This method was satisfactorily applied for the determination of BPs in 16 placental tissue samples collected from women who live in Granada (Spain).     

Determination of faropenem in human plasma and urine by liquid chromatography-tandem mass spectrometry

A simple, rapid and sensitive liquid chromatography/electrospray tandem mass spectrometry (LC-MS/MS) quantitative detection method, using cefalexin as internal standard, was developed for the analysis of faropenem in human plasma and urine. After precipitation of the plasma proteins with acetonitrile, the analytes were separated on a C18 reversed-phase column with 0.1% formic acid-methanol (45:55, v/v) and detected by electrospray ionization mass spectrometry in positive multiple reaction monitoring mode. Calibration curves with good linearities (r=0.9991 for plasma sample and r=0.9993 for urine sample) were obtained in the range 5-4000 ng/mL for faropenem. The limit of detection was 5 ng/mL. Recoveries were around 90% for the extraction from human plasma, and good precision and accuracy were achieved. This method is feasible for the evaluation of pharmacokinetic profiles of faropenem in humans, and to our knowledge, it is the first time the pharmacokinetic of faropenem has been elucidated in vivo using LC-MS/MS.     

Simultaneous profiling of lysophospholipids and phospholipids from human plasma by nanoflow liquid chromatography-tandem mass spectrometry

In this study, an analytical method for the simultaneous separation and characterization of various molecular species of lysophospholipids (LPLs) and phospholipids (PLs) is introduced by employing nanoflow liquid chromatography-electrospray ionization tandem mass spectrometry (nLC-ESI-MS/MS). Since LPLs and PLs in human plasma are potential biomarkers for cancer, development of a sophisticated analytical method for the simultaneous profiling of these molecules is important. Standard species of LPLs and PLs were examined to establish a separation condition using a capillary LC column followed by MS scans and data-dependent collision-induced dissociation (CID) analysis for structural identification. With nLC-ESI-MS/MS, regioisomers of each category of LPLs were completely separated and identified with characteristic CID spectra. It was applied to the comprehensive profiling of LPLs and PLs from a human blood plasma sample and yielded identifications of 50 LPLs (each regioisomer pair of 6 lysophosphatidylcholines (LPCs), 7 lysophosphatidylethanolamines (LPEs), 9 lysophosphatidic acid (LPAs), 2 lysophosphatidylglycerols (LPGs), and 1 lysophosphatidylserine (LPS)) and 62 PLs (19 phosphatidylcholines (PCs), 11 phosphatidylethanolamines (PEs), 3 phosphatidylserines (PSs), 16 phosphatidylinositols (PIs), 8 phosphatidylglycerols (PGs), and 5 phosphatidic acids (PAs)).     

Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry

Chemically modified steroids (designer steroids), including tetrahydrogestrinone and norbolethone, pose a threat to the integrity of the sport community. These compounds have recently been detected in urine specimens from athletes, resulting in temporary or permanent suspension from amateur and/or professional competition. Triple quadrupole mass spectrometers enable doping control laboratories to screen for unknown, anabolic, androgenic steroids utilizing precursor ion scans. On the basis of common dissociation patterns of steroids with common structural features, characteristic product ions were selected to serve as diagnostic markers for previously unidentified drugs or drug metabolites in human urine samples. An assay was established to complement standard screening procedures. Urine specimens were enzymically hydrolyzed, partitioned into ether, concentrated, and analyzed by precursor ion scanning. Spectra from samples fortified with eight standard compounds (methyltestosterone, ethyltestosterone, 1-testosterone, gestrinone, dihydrogestrinone, tetrahydrogestrinone, norbolethone, and propyltrenbolone) and one deuterium-labeled analog (d(4)-tetrahydrogestrinone) at 50 ng/ml of urine, had precursor ion peaks other than those from common endogenous steroids. Subsequent product ion scan experiments on precursor ions of peaks of unknown origin provided structural identification of the unknown compounds.     

超高效液相色谱-串联质谱法测定畜禽毛发中利巴韦林及其代谢物

建立了一种测定畜禽毛发中利巴韦林及其代谢物1H-1,2,4-三氮唑-3-甲酰胺(TCONH2)残留的检测方法。1%十二烷基硫酸钠清洗毛发,2%甲酸-甲醇(2:98,V/V)溶液提取,13C-利巴韦林(13CRBV)内标法定量,乙二胺-N-丙基硅烷(PSA)和十八烷基硅烷(C18)基质分散净化,Agilent ZORBAX SB-Aq色谱柱分离,电喷雾串联质谱多反应监测模式测定。利巴韦林和TCONH2在毛发中线性关系良好(R^2>0.99)在2,10,100μg/kg3个添加水平下利巴韦林和代谢物TCONH2的回收率分别为101.5%~108.5%和98.5%~101.5%相对标准偏差均小于7%,检出限和定量限分别为0.2μg/kg和0.5μg/kg。该方法适合于畜禽毛发中违禁抗病毒药物利巴韦林及其代谢物TCONH2的测定。     

液相色谱-串联质谱法测定水环境中的十氯酮

建立了分析测定水环境中十氯酮的液相色谱-串联质谱法。水样经液液萃取、净化后,采用Eclipse plus C18柱（100 mm×2.1 mm,3.5 μm）分离,乙腈和水为流动相进行梯度洗脱,在电喷雾负离子多反应监测模式下进行检测,同位素内标法定量。结果表明：采用液相色谱-质谱联用技术,证实了十氯酮在甲醇中以半缩醛的形式存在,而在丙酮/乙腈中以偕二醇的形式存在。由于十氯酮极性较强,在净化时难以洗脱,并且不耐酸,所以不能与其他有机氯农药一起分析。十氯酮在5~100 μg/L范围有良好的线性关系,相关系数r²=0.999,检出限及定量限分别为0.70 ng/L和2.8 ng/L;在5、40和100 ng/L 3个浓度添加水平的平均回收率为95.1%~98.9%,相对标准偏差为3.85%~4.72%。本方法具有良好的灵敏度、回收率和重现性,适用于水环境中十氯酮的测定。     

Quantification of human pharmaceuticals in water samples by high performance liquid chromatography-tandem mass spectrometry

An improved analytical method for determination of human pharmaceuticals in natural and wastewaters with ng L⁻¹ sensitivity is presented. The method is applicable to pharmaceuticals from a wide range of therapeutic classes including antibiotics, analgesics, anti-inflammatories and anti-cancer compounds. Pharmaceuticals were extracted from waters using solid-phase extraction, and after concentration, analysed by high performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS). Identification of each compound was secured using retention time and by the selected reaction monitoring of two transitions, one of which was additionally used for quantification. Limits of detection ranged from 0.03 to 0.96 ng L⁻¹ and were up to two orders of magnitude lower than those of previously published methods. The method was validated using spiked samples prepared from tap, river and sea water as well as wastewater effluents, collected from the North of Scotland. Analysis of wastewater effluents revealed the presence of mefenamic acid, ibuprofen, erythromycin, diclofenac and trimethoprim. None of the selected pharmaceuticals were detected in river, tap or sea water samples.     

Simultaneous determination of paracetamol and chlorpheniramine in human plasma by liquid chromatography-tandem mass spectrometry

An analytical method for the determination of paracetamol and chlorpheniramine in human plasma has been developed, validated and applied to the analysis of samples from a phase I clinical trial. The analytical method consists in the extraction of paracetamol and chlorpheniramine with diethyl ether, followed by the determination of both drugs by an LC–MS–MS method, using 2-acetamidophenol as internal standard. The intra-assay and inter-assay precision and accuracy of this technique were good and the limit of quantitation was 0.5 μg/ml of plasma for paracetamol and 0.2 ng/ml for chlorpheniramine. The concentration working range was established between 0.5 μg/ml and 25 μg/ml for paracetamol and between 0.2 ng/ml and 50 ng/ml for chlorpheniramine. This method has been used for analyzing more than 1200 human plasma samples from a clinical study with 24 volunteers.     

超高效液相色谱-串联质谱法测定人血浆中苯海索

建立了灵敏、高通量的超高效液相色谱-串联质谱（UPLC-MS/MS）定量测定人血浆中苯海索的方法,用于盐酸苯海索片生物等效性研究,并确证食物对苯海索体内药代动力学行为的影响。以甲醇为沉淀剂进行蛋白质沉淀,苯海索-d11为内标,采用Waters Acquity UPLC BEH C8色谱柱（50 mm×2.1mm,1.7 μm）,以0.1%（v/v）甲酸水溶液（含5 mmol/L醋酸铵）和乙腈-水（95：5,v/v）为流动相进行梯度洗脱;采用电喷雾电离（ESI）源,在正离子模式下进行多反应监测（MRM）扫描。苯海索在0.1~40 ng/mL范围内线性关系良好。应用该方法测定中国健康受试者空腹及餐后单次口服2 mg盐酸苯海索片后的血药浓度,结果显示最大血药浓度（C_max）、血药浓度-时间曲线下面积（AUC_0-t、AUC_0-∞）的90%置信区间均在80.0%~125.0%范围内,表明两种制剂在空腹和餐后均生物等效。     

Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry

A method has been developed for the simultaneous quantification of metformin (I) and glipizide (II) in human plasma. It is based on high-performance liquid chromatography with electrospray ionization tandem mass (LC-ESI-MS/MS) spectrometric detection in positive ionization mode. Phenformin (III) and gliclazide (IV) were used as internal standards for I and II, respectively. The MS/MS detection was performed in multiple reaction monitoring (MRM) mode. The precursor-product ion combinations of m/z 130 --> 71, 446 --> 321, 206 --> 60 and 324 --> 127 were used to quantify I, II, III and IV, respectively. This method was validated in the concentration ranges of 0.02-4 microg/mL for I and 0.004-0.8 microg/mL for II. It was utilized to support a clinical pharmacokinetic study after single dose oral administration of a combination of I and II.     

Simultaneous determination of chlorpheniramine and pseudoephedrine in human plasma by liquid chromatography-tandem mass spectrometry

A sensitive and specific procedure for simultaneous quantitation of chlorpheniramine and pseudoephedrine in human plasma has been developed and validated. Analytes were extracted from plasma samples by liquid-liquid extraction, separated on a Diamonsil C18 column (250 x 4.6 mm i.d.) and detected by tandem mass spectrometry with an atmospheric pressure chemical ionization interface. Diphenhydramine was used as the internal standard. The method has a lower limit of quantitation of 0.2 and 2.0 ng/mL for chlorpheniramine and pseudoephedrine, respectively. The intra- and inter-day relative standard deviation, calculated from quality control (QC) samples were below 4.3% for chlorpheniramine and below 9.5% for pseudoephedrine. The inter-day relative error as determined from QC samples was within 4.7% for each analyte. The overall extraction recoveries of chlorpheniramine and pseudoephedrine were 77 and 61% on average, respectively. The method was successfully applied to pharmaockinetic study of chlorpheniramine and pseudoephedrine in volunteers receiving formulations containing 4 mg of chlorpheniramine maleate and 60 mg of pseudoephedrine hydrochloride.     

Simultaneous determination of beta-blockers in human plasma using liquid chromatography-tandem mass spectrometry

A detailed procedure for the analysis of four beta-blockers, acebutolol, labetalol, metoprolol and propranolol, in human plasma by high-performance liquid chromatography (LC)-tandem mass spectrometry (MS-MS) using an MSpak GF column, which enables direct injection of crude plasma samples, is presented. Protein and/or macromolecule matrix compounds were eluted first from the column, while the drugs were retained on the polymer stationary phase of the MSpak GF column. The analytes retained on the column were then eluted into an acetonitrile-rich mobile phase using a gradient separation technique. All drugs showed base peak ions due to [M + H]+ ions by LC-MS with positive ion electrospray ionization, and the product ions were produced from each [M + H]+ ion by LC-MS-MS. Quantification was performed by selected reaction monitoring. The recoveries of the four beta-blockers spiked into plasma were 73.5-89.9%. The regression equations for all compounds showed excellent linearity in the range 10-1000 ng/mL of plasma, with the exception of propranolol (10-800 ng/mL). The limits of detection and quantification for each drug were 1-3 and 10 ng/mL, respectively, of plasma. The intra- and inter-day coefficients of variation for all drugs in plasma were not greater than 10.9%.